CORRECTION article

Front. Immunol., 16 July 2025

Sec. Cancer Immunity and Immunotherapy

Volume 16 - 2025 | https://doi.org/10.3389/fimmu.2025.1654196

Correction: Case Report: Regenerative hepatic pseudotumor induced by tislelizumab in a lung cancer patient

  • 1. Digestive Diseases Center, Department of Hepatopancreatobiliary Medicine, The Second Hospital, Jilin University, Changchun, China

  • 2. Department of Respiratory and Critical Care Medicine, The Second Hospital of Jilin University, Changchun, Jilin, China

  • 3. Department of Radiology, The Second Hospital of Jilin University, Changchun, China

In the published article, there was an error in the Funding statement. The funder “Natural Science Foundation of Jilin Province (YDZJ202501ZYTS814 and YDZJ202401255ZYTS) to Wenrui Wang” was erroneously omitted.

The correct Funding statement appears below.

“The author(s) declare that financial support was received for the research and/or publication of this article. Natural Science Foundation of Jilin Province (YDZJ202501ZYTS814 and YDZJ202401255ZYT) provided funding to author Wenrui Wang.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Statements

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

immune checkpoint inhibitors, immune-related adverse events, non-small cell lung cancer, regenerative hepatic pseudotumor, tislelizumab, hepatic immune toxicity, PD-1 inhibitors, immunotherapy complications

Citation

Wang W, Li W, Zhang T, Jin Z and Yang L (2025) Correction: Case Report: Regenerative hepatic pseudotumor induced by tislelizumab in a lung cancer patient. Front. Immunol. 16:1654196. doi: 10.3389/fimmu.2025.1654196

Received

26 June 2025

Accepted

07 July 2025

Published

16 July 2025

Approved by

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Volume

16 - 2025

Updates

Copyright

*Correspondence: Lanlan Yang,

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics